WAVE Life Sciences (WVE) stock is soaring 5.04% in intraday trading on Tuesday, showing resilience despite reporting worse-than-expected third-quarter financial results. The biotechnology company's shares are demonstrating strength even as analysts offer mixed views on its future prospects.

WAVE Life Sciences reported a quarterly loss of 32 cents per share, missing the analyst consensus estimate of a 30 cents per share loss. The company's quarterly sales of $7.608 million also fell short of the expected $11.130 million. However, investors appear to be focusing on the company's progress in key clinical objectives, particularly in obesity and alpha-1 antitrypsin deficiency treatments.

Following the earnings announcement, analysts have revised their forecasts for WAVE Life Sciences. Wells Fargo maintained an Overweight rating but lowered its price target from $18 to $16. In contrast, Wedbush reiterated its Outperform rating and raised its price target from $18 to $20. The divergent analyst actions reflect the complex landscape WAVE Life Sciences is navigating, balancing near-term financial performance with long-term clinical potential. Despite the mixed signals, the stock's upward movement suggests that investors are optimistic about the company's future, particularly its potential to disrupt the obesity treatment landscape with its non-incretin approach.